Roche Receives FDA Approval for New Indication for cobas EGFR Mutation Test v2 as a Companion Diagnostic With Tagrisso

Roche Receives FDA Approval for New Indication for cobas EGFR Mutation Test v2 as a Companion Diagnostic With Tagrisso

Submitted by admin on April 19, 2018 - 12:30am
Source: 
CP Wire
News Tags: 
Roche
cobas EGFR Mutation Test
Tagrisso
non-small cell lung cancer
AstraZeneca
Headline: 
Roche Receives FDA Approval for New Indication for cobas EGFR Mutation Test v2 as a Companion Diagnostic With Tagrisso
snippet: 
  • New indication as a companion diagnostic with AstraZeneca's Tagrisso (osimertinib) in first line treatment of patients with non-small cell lung cancer (NSCLC)
  • Results for EGFR mutations can be available in less than one day with the cobas EGFR Mutation Test v2 to determine if patients can benefit from Tagrisso

Do Not Allow Advertisers to Use My Personal information